T-MAXIMUM Pharmaceutical

T-MAXIMUM's MT027 Wins FDA Phase 2 Clearance in Brain Metastases

Image
T-MAXIMUM's MT027 Wins FDA Phase 2 Clearance in Brain Metastases

Beijing – October 13, 2026 -- T-MAXIMUM PHARMACEUTICAL has received FDA clearance to start a Phase 2 study of MT027, its B7-H3-targeted allogeneic CAR-T therapy, in patients with brain metastases from lung and breast cancer. It is the second Phase 2 program for the asset to clear the agency.

MT027 now has two FDA-cleared Phase 2 programs in intracranial solid tumors

The FDA previously cleared a Phase 2 study of MT027 in recurrent glioblastoma. The therapy holds Orphan Drug Designation and Fast Track Designation. The two programs give T-MAXIMUM a dual-indication portfolio covering both primary and metastatic intracranial solid tumors.

T-MAXIMUM's Allogeneic CAR-T Shows 80% Tumor Shrinkage in Brain Metastases

Beijing – September 21, 2026 -- T-MAXIMUM Pharmaceutical reported that two of three evaluable patients with refractory brain metastases from lung cancer achieved partial responses with roughly 80% tumor shrinkage after treatment with its allogeneic B7-H3-targeted CAR-T therapy, MT027, according to early data presented at the IASLC World Conference on Lung Cancer (WCLC 2026) in Seoul.

Two of three evaluable patients hit 80% tumor shrinkage in dose-escalation trial

In the prospective, investigator-initiated trial (ChiCTR2500107346), five patients with heavily pretreated, guideline-exhausted brain metastases completed treatment. Of the three with measurable disease, two achieved partial responses and one achieved stable disease. As of the company's September 2026 follow-up, the two responders have survived more than 11 and 13 months, respectively, since their first MT027 dose, and all three evaluable patients remain alive.